

1 **Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma**

2

3 Samantha K Davis<sup>1</sup>, Kevin John Selva<sup>1</sup>, Ester Lopez<sup>1</sup>, Ebene R Haycroft<sup>1</sup>, Wen Shi Lee<sup>1,2</sup>, Adam  
4 K Wheatley<sup>1</sup>, Jennifer A Juno<sup>1</sup>, Amy Adair<sup>2</sup>, Phillip Pymm<sup>2</sup>, Samuel J Redmond<sup>1</sup>, Nicholas A  
5 Gherardin<sup>1</sup>, Dale I Godfrey<sup>1</sup>, Wai-Hong Tham<sup>2</sup>, Stephen J Kent<sup>1,3\*</sup>, Amy W Chung<sup>1\*</sup>.

6

7 1 Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and  
8 Immunity, University of Melbourne, Melbourne, Victoria

9 2 The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia

10 3 Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital  
11 and Central Clinical School, Monash University, Melbourne, Victoria, Australia

12

13 \*Contributed equally, correspondence to: Amy Chung [awchung@unimelb.edu.au](mailto:awchung@unimelb.edu.au) or  
14 Stephen Kent [skent@unimelb.edu.au](mailto:skent@unimelb.edu.au)

15

16

17

18 **Abstract**

19 Following infection with SARS-CoV-2, virus-specific antibodies are generated which can both  
20 neutralise virions and clear infection via Fc effector functions. The importance of IgG  
21 antibodies for protection and control of SARS-CoV-2 has been extensively reported. In  
22 comparison, other antibody isotypes including IgA have been poorly characterized. Here we  
23 characterized plasma IgA from 41 early convalescent COVID-19 subjects for neutralisation and  
24 Fc effector functions. We find that convalescent plasma IgA from >60% of the cohort have the  
25 capacity to inhibit the interaction between wild-type RBD and ACE2. Furthermore, a third of  
26 the cohort induced stronger IgA-mediated inhibition of RBD binding to ACE2 than IgG, when  
27 tested at equivalent concentrations. Plasma IgA and IgG from the cohort, broadly recognize  
28 similar RBD epitopes and showed similar ability to inhibit ACE2 from binding 22 of 23 different  
29 prevalent RBD proteins with single amino acid mutations. Plasma IgA was largely incapable of  
30 mediating antibody-dependent phagocytosis in comparison to plasma IgG. Overall,  
31 convalescent plasma IgA contributes to neutralisation towards wild-type RBD and various RBD  
32 single mutants in most subjects, although this response is heterogeneous and less potent than  
33 IgG.

34

35 **Running Title:** Heterologous SARS-CoV-2 IgA Neutralisation

36

37 **Key Words:** SARS-CoV2, IgA, Neutralisation, Fc function, RBD, ACE2 inhibition

## 38 Introduction

39 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of  
40 Coronavirus disease 2019 (COVID-19) has infected millions of people and caused over 5.6  
41 million deaths globally since its discovery. SARS-CoV-2 trimeric spike protein consists of two  
42 domains; spike 1 (S1) and spike 2 (S2) (Wrapp et al., 2020). The receptor binding domain (RBD)  
43 within the S1 engages with angiotensin-converting enzyme 2 (ACE2) on human cells  
44 contributing to infection (Wrapp et al., 2020). Antibodies generated towards RBD following  
45 infection or vaccination can block engagement with ACE2 and neutralise SARS-CoV-2 (Collier  
46 et al., 2021; Lustig et al., 2021; Wheatley et al., 2021). Mutations within the RBD can generate  
47 variants that have improved transmissibility and can lead to escape of antibody immunity  
48 from vaccination or infection, thus potentially becoming variants of concern (VOC) (Dupont  
49 et al., 2021; Falsey et al., 2021; Rössler et al., 2021). Importantly, both neutralising and non-  
50 neutralising antibodies engage fragment crystallisable (Fc) receptors on immune cells (e.g.  
51 monocytes) to activate Fc effector functions to clear infection (Chan et al., 2021; Tauzin et al.,  
52 2021; Ullah et al., 2021; Winkler et al., 2021). This polyfunctional antibody response assists in  
53 protection and control of viral infections, such a SARS-CoV-2 (Natarajan, Crowley, et al.,  
54 2021a; Sadarangani et al., 2021).

55

56 SARS-CoV-2 infection and vaccine-induced plasma antibodies directed towards RBD have  
57 been widely reported to neutralise SARS-CoV-2 using the fragment antigen binding (Fab)  
58 portion (Devarasetti et al., 2021; Lopez et al., 2021; Wheatley et al., 2021). Convalescent  
59 plasma IgG and IgM have been heavily studied, with both isotypes playing a large role in the  
60 neutralising response to SARS-COV-2 wild-type (WT) and VOC's (Gasser et al., 2021; Liu et al.,  
61 2020; Maeda et al., 2021). Limited studies suggest plasma IgA dominates neutralisation of  
62 SARS-CoV-2 WT during early infection and decreases into convalescence (Klingler et al., 2020;  
63 Sterlin et al., 2021). Importantly, some IgA monoclonal antibodies (mAb's) (monomeric and  
64 dimeric) can neutralise SARS-CoV-2 WT very effectively (Ejemel et al., 2020; Wang et al.,  
65 2021). The importance of plasma IgA induced by infection with SARS-CoV-2 WT and their  
66 capacity to inhibit ACE2 binding to RBD mutants remains to be assessed.

67

68 Neutralising and non-neutralising antibodies, including IgG and IgA, can engage Fc receptors  
69 (FcγR and FcαR respectively) on immune cells and activate Fc effector functions to clear viral

70 infection (Asokan et al., 2020; Blutt et al., 2012; Davis et al., 2020). Effector functions including  
71 complement activation, phagocytosis, and antibody dependent cellular cytotoxicity (ADCC)  
72 have been implicated in clearance and control of SARS-CoV-2 infection (Dufloo et al., 2021;  
73 Lee et al., 2021; Natarajan et al., 2021). Importantly, compromised Fc effector function and  
74 reduced neutralising potency have been linked to poorer disease outcomes in humans  
75 (Garcia-Beltran et al., 2021; Zohar et al., 2020). The necessity for a polyfunctional IgG antibody  
76 response has also been highlighted in animal models, where neutralising human IgG  
77 monoclonal antibody (mAb) therapy protects from SARS-CoV-2 infection when given as a  
78 prophylactic mAb but requires additional Fc functions for optimal protection when given as a  
79 therapeutic (Chan et al., 2021; Winkler et al., 2021). However, the importance of plasma IgA  
80 for optimal Fc effector function has yet to be characterised.

81  
82 The functional capacity of polyclonal convalescent IgA to SARS-CoV-2 has yet to be  
83 characterised, especially to RBD mutations associated with VOC. Here we examined purified  
84 fractions of plasma and purified IgA and IgG, to investigate the contribution of these isotypes  
85 to the polyclonal convalescent antibody response to RBD and prevalent single amino acid RBD  
86 mutants.

87

## 88 **Results**

### 89 **Robust antibody recognition and ACE2 binding inhibition by SARS-CoV-2 convalescent** 90 **plasma**

91 41 SARS-CoV-2 convalescent subjects (median age of 55; IQR 49-61) ~41 days post symptom  
92 onset and 26 uninfected subjects (mean age of 54; IQR 24-60) donated plasma samples (sup.  
93 table 1.). To determine Spike-1 (S1) and RBD wild-type (RBDWT) antibody binding,  
94 convalescent and uninfected subject plasma were assessed for IgM, IgG, and IgA binding using  
95 a SARS-CoV-2 multiplex bead array (Selva et al., 2021b) (fig. 1, sup. fig. 1a-c). Most SARS-CoV-  
96 2 convalescent subjects generated IgM, IgG, and IgA antibodies to RBDWT (IgM: 73.15%  
97 positive, median MFI=54086; IgG: 100% positive, median MFI=45745; IgA 97.56% positive,  
98 median MFI=2495) (fig. 1a-c).

99

100 To examine the ability of subject plasma to neutralise SARS-CoV-2, we used a multiplex  
101 RBDWT-ACE2 binding inhibition assay, that has been demonstrated to highly correlate with

102 gold standard live microneutralization assays (Lopez et al., 2021). Almost all convalescent  
103 subjects (95.12%) generated significant inhibition of ACE2 binding to RBDWT  
104 (median=73.23%, with ACE2 binding inhibition <20% considered to be below the limit of  
105 detection (Lopez et al., 2021)) (fig. 1d). Significant S1-ACE2 binding inhibition was also observed  
106 for convalescent subject plasma compared to uninfected subjects (sup. fig. 1d & e). Thus,  
107 most SARS-CoV-2 convalescent plasma induced antibodies that recognise RBDWT and have  
108 the capacity to inhibit the binding of RBD to ACE2, as previously reported (Lopez et al., 2021).  
109  
110 RBDWT antibody isotype titres (IgG, IgM and IgA) have previously been correlated to the level  
111 of plasma neutralisation or ACE2 binding inhibition (Gasser et al., 2021; Lopez et al., 2021;  
112 Sterlin et al., 2021). Here the cohort was broken down by isotype seropositivity and the ability  
113 to block ACE2 engagement with RBDWT to observe the surface level contribution of the  
114 isotypes to neutralisation in this cohort (fig. 1e). The majority (68.29%, 28 out of 41) of the  
115 convalescent cohort were seropositive for all 3 isotypes (RBDWT IgM, IgG and IgA) with 100%  
116 (28 out of 28) of these individuals being positive for ACE2 binding inhibition (fig. 1e). 29.27%  
117 (12 out of 41) of the cohort were seronegative for IgM but seropositive for IgG and IgA, with  
118 83.33% (10 out of 12) of these individuals being positive for ACE2 binding inhibition (fig. 1e).  
119 A single individual (2.44% of the cohort) was seronegative for IgA but seropositive for IgM and  
120 IgG and could mediate ACE2 binding inhibition (fig. 1e). To investigate the combined  
121 contribution of anti-RBDWT antibody isotypes (IgG, IgM and IgA) to ACE2 binding inhibition,  
122 we performed partial least squares regression (PLSR) (fig. 1f-g). Not surprisingly, plasma  
123 samples with the highest ACE2 inhibition (yellow – highest, dark blue weakest ACE2 inhibition)  
124 predominantly cluster together across Latent Variable 1 (X- axis fig. 1f) and were strongly  
125 associated with anti-RBDWT antibody isotype titres, with IgG and IgM being the strongest  
126 correlates (fig. 1g). This was further confirmed by individual correlations with anti-RBDWT  
127 antibody isotypes (sup. fig. 2). Similar trends were observed for S1 (sup. fig. 1a-e). This data  
128 highlights that robust anti-RBDWT IgM, IgG and IgA response develops against SARS-CoV-2  
129 and persist during early convalescence.

130

### 131 **IgA and IgG antibody depletion from convalescent plasma reduces ACE2 binding inhibition**

132 IgG has been shown to play a critical role in plasma neutralisation to various viral infections,  
133 including SARS-CoV-2 (W. T. Lee et al., 2021; Lopez et al., 2021; Maeda et al., 2021). However,

134 the contribution of plasma IgA to the convalescent SARS-CoV-2 neutralising antibody  
135 response, especially to emerging RBD mutants remains unclear (Sterlin et al., 2021; Verkerke  
136 et al., 2021; Wang et al., 2021). To define the contribution of IgG and IgA to the neutralising  
137 capacity of convalescent plasma, we depleted IgA from plasma (IgA- plasma) and also  
138 depleted plasma of both IgA and IgG (IgA- and IgG- depleted plasma) to assess the capacity  
139 of antibody depleted plasma fractions to inhibit RBDWT binding to ACE2 (fig. 2, sup. fig. 3).  
140 Successful IgG and IgA depletion was confirmed by a significant reduction in IgA and IgG  
141 binding to RBDWT ( $p < 0.0001$ ) and S1 ( $p < 0.0001$ ) for IgA- and IgA-/IgG- plasma (sup. fig. 3f-g,  
142 i-j). 73.2% (30 out of 41) of convalescent IgA- plasma samples were successfully depleted of  
143 IgA and had  $< 30\%$  loss of IgG or IgM (sup. fig. 3b).

144  
145 ACE2 binding inhibition of whole plasma at 1:100 was compared to matched dilutions of IgA-  
146 and IgA-/IgG- plasma to investigate the contribution of IgA and IgG to convalescent plasma  
147 neutralisation (fig. 2). IgA depletion reduced the capacity for convalescent plasma to mediate  
148 RBDWT-ACE2 binding inhibition by 22.14% (IgA depletion: median ACE2 inhibition=41.24%,  
149 IQR 19.19%-65.41%,) compared to matched complete convalescent plasma (median ACE2  
150 inhibition=63.38%, IQR 35.03%-75.92%,  $p = 0.0001$ ) (fig. 2a). We also investigated the  
151 contribution of IgG to convalescent plasma neutralisation. IgG depletion (IgA-/IgG- plasma)  
152 further reduced RBDWT-ACE2 binding inhibition by 15.68% (median ACE2 inhibition= 25.56%,  
153 IQR 14.64%-33.96%,  $p = 0.08$ ) compared to IgA- plasma (fig. 2a). Similar trends were observed  
154 for S1 (sup. fig. 1f-h). This data suggests both IgA and IgG contributes to the neutralising  
155 capacity of convalescent plasma for most individuals in this cohort.

156  
157 **The contribution of convalescent purified IgA to RBDWT-ACE2 binding inhibition is**  
158 **heterogenous**

159 Although the above depletion studies suggest IgA contributes to convalescent plasma  
160 neutralisation in the majority of the cohort, a more definitive role of IgA or IgG in  
161 neutralisation could be revealed by specifically purifying these fractions and measuring  
162 antibody binding using a multiplex bead array. First, we investigated the capacity for purified  
163 IgG and IgA to mediate ACE2 binding inhibition to RBDWT at  $100\mu\text{g/ml}$  total antibody. Purified  
164 convalescent IgG (median=27.01% IQR 13-37%-41.87%) and IgA (median=12.17% IQR 0-  
165 31.39) mediated increased RBDWT-ACE2 binding inhibition compared to purified IgA

166 (median=12.57% IQR=5.633%-13.22%) and IgG (median=21.69% IQR=14.60-29.01) from  
167 uninfected donors, although this increase was not significant (IgA  $p=0.7810$ ; IgG  $p=0.5665$ )  
168 (sup. fig. 4a-h). Not surprisingly a smaller proportion of individuals had detectable  
169 neutralization levels (>20% ACE2 inhibition; Purified IgA: 26.5% and Purified IgG: 59.18% of  
170 individuals, sup. fig 4c, f-h), than predicted by the IgA/IgG depletion experiments, likely due  
171 to the low concentration of purified IgA (100 $\mu$ g/ml) antibody available for use in these assays.  
172

173 We next compared the ACE2 inhibitory capacity of matched purified IgG and IgA from the  
174 same individuals at equivalent total purified antibody concentrations (100 $\mu$ g/ml). Overall,  
175 within this cohort IgG mediated significantly higher ACE2 binding inhibition compared to IgA  
176 ( $p=0.0045$ ) (sup. fig. 4h). However, examining this cohort in greater detail, while 69.39% (34  
177 out of 49) individuals had lower IgA mediated ACE2 binding inhibition (fig. 2b, sup. fig 4h),  
178 interestingly, 30.1% (15 out of 49) of individuals mediated stronger ACE2 binding inhibition  
179 via IgA instead of IgG (fig. 2c). Furthermore, the top 3 purified IgA neutralisers had  
180 comparable IgA mediated neutralisation when compared to the top 3 purified IgG neutralisers  
181 (fig. 2b & c). Similar trends were observed for S1 antibody binding and ACE2 binding inhibition  
182 for purified convalescent IgG and IgA (sup. fig. 4a-c). We also demonstrate that the level of  
183 RBD-specific antibody binding correlated with ACE2 binding inhibition for both purified IgA  
184 ( $r=0.61$ ,  $p<0.0001$ ) and IgG ( $r=0.84$ ,  $p<0.0001$ ) (fig. 2d), suggesting that both IgG and IgA have  
185 the potential to neutralise SARS-CoV-2, however this is largely dependent on anti-RBDWT  
186 antibody titre/ concentration.

187  
188 To confirm the importance of antibody titre for an individual's ability to facilitate IgA  
189 mediated ACE2 binding inhibition, increasing concentrations of purified IgA (12.5, 50 and  
190 100 $\mu$ g/ml total antibody) were spiked back into IgA- plasma from individuals with IgA  
191 mediated ACE2 binding inhibition (>20%) where sufficient sample was available ( $n=3$ ) (fig. 2e).  
192 RBDWT-ACE2 binding inhibition of IgA- plasma increased with increasing concentrations of  
193 IgA, with a 2.98-fold increase in RBDWT-ACE2 binding inhibition compared to IgA- plasma  
194 (median ACE2 inhibition=26.43% IQR=14.98%-35.50%) with addition of 100 $\mu$ g/ml purified IgA  
195 (median ACE2 inhibition=40.61% IQR=34.05%-67.55%) (fig. 2f).

196



197 Intriguingly, upon further examination, we identified a small subset of individuals (n=3),  
198 where depletion of IgA resulted in a small increase in ACE2 inhibition (fig. 2g) (plasma: median  
199 ACE2 inhibition= 54.41%, IgA depleted plasma: median ACE2 inhibition= 59.41%). We selected  
200 the individual with the strongest level of RBDWT-ACE2 binding inhibition (CP30), and purified  
201 IgA was spiked back into IgA depleted plasma at increasing concentrations for this individual.  
202 IgM binding decreased (0.2-fold reduction, fig. 2h), whereas RBDWT-ACE2 binding inhibition  
203 (0.5-fold increase, fig. 2i) surprisingly increased by the addition of 100µg/ml purified IgA.  
204 These results demonstrate that in rare individuals, at higher titers, IgA may be able to block  
205 RBD-specific IgM/IgG from binding, thus inhibiting ACE2 inhibition by other isotypes. This  
206 inhibition is likely through IgA binding to non-neutralising epitope(s), thus blocking the  
207 binding of other neutralising antibodies isotypes.

208

#### 209 **Antibody binding profiles of SARS-CoV-2 convalescent purified IgG and IgA to RBD single** 210 **mutants**

211 SARS-CoV-2 variants are rapidly emerging, that include amino acid mutations within the RBD,  
212 some of which confer increased ACE2 affinity and antibody escape (Harvey et al., 2021; Verma  
213 & Subbarao, 2021). The capacity for IgG mAbs, convalescent plasma and plasma IgG to  
214 recognise different RBD mutations has been widely characterised, however, the capacity of  
215 convalescent purified IgA to recognise different RBD mutations is yet to be reported (Lopez  
216 et al., 2021; Maeda et al., 2021). To explore the impact of RBD mutations on IgA and IgG  
217 driven ACE2 binding inhibition, plasma, IgA- depleted plasma and IgA-/IgG- depleted plasma  
218 were assessed for ACE2 binding inhibition to a panel of 23 RBD single amino acid mutants,  
219 using a previously published competitive RBD-ACE2 inhibition multiplex assay (Lopez et al.,  
220 2021). As expected, weaker whole plasma ACE2 inhibition was observed for a number of RBD  
221 single amino acid mutations including E484K (present in Beta and Gamma VOC) and N501Y  
222 (present in Beta, Gamma and Omicron) as compared to RBD-WT, as previously described  
223 (Lopez et al., 2021). Depletion of IgA and IgG also reduced RBD-ACE2 inhibition levels across  
224 all RBD variants, suggesting that IgA and IgG contribute to the recognition of RBD variants (fig.  
225 3a, sup. fig. 5a).

226

227 To further characterise the IgA and IgG-driven ACE2 binding inhibition to RBD mutations,  
228 individuals who mediated stronger IgA-mediated RBDWT-ACE2 binding inhibition (median:



229 28.31%, n=13) were characterised further for their matched purified IgG and IgA binding and  
230 ACE2 binding inhibition to 23 RBD single amino acid mutations (fig. 3b-e). First, antibody  
231 binding relative to RBDWT for 23 RBD single mutants was calculated using EC<sub>50</sub> values  
232 obtained from the normalised antibody binding MFI for matched convalescent purified IgA  
233 and IgG samples (titrations up to 100µg/ml) (fig. 3b & d, sup. fig. 5b). Importantly, for 18 of  
234 the 23 mutants (78.26%) there was no significant difference in antibody binding for purified  
235 IgG and IgA (fig. 3b & d). Overall, IgG trended towards better antibody binding (lower EC<sub>50</sub>)  
236 compared to IgA, with 5 RBD mutants (L455F (p= 0.0153), N439K (p=0.0153), T478I  
237 (p=0.0107), K444R (p=0.0056) and V483F (p=0.032), all p-values adjusted for multiple  
238 comparison) having significantly greater IgG recognition compared to IgA using multiple  
239 comparisons (fig. 3b & d). Interestingly, the RBD mutant G446V showed a trend towards  
240 (adjusted p=0.0956) better IgA recognition relative to RBDWT (median EC<sub>50</sub>=157.7 IQR=68.86-  
241 180.9) compared to IgG (median EC<sub>50</sub>=246.5 IQR=108.9-400) (fig. 3b & d, sup. fig. 5b). Notably,  
242 we observed a larger range in fold change for individual IgA binding (median range of fold  
243 change across all variants=7.017) relative to RBDWT for the 23 RBD mutants compared to IgG  
244 (median range of fold change across all variants=0.64) (fig. 3b). This data suggests IgG and IgA  
245 can recognise RBD mutations similarly.

246

247 We next investigated if differences in antibody recognition by IgG and IgA translated to a  
248 difference in ACE2 binding inhibition. We assessed the ACE2 binding inhibition capacity of  
249 purified IgA and IgG for the same IgA neutralisers (n=13) to 23 RBD single mutants at a single  
250 concentration (100µg/ml total antibody) using the previously described multiplex ACE2-  
251 inhibition array (fig. 3c & e). Purified IgG had significantly increased ACE2 binding inhibition  
252 relative to RBDWT compared to purified IgA for 1 RBD mutation (G476S) (p=0.011) (fig. 3c).  
253 Purified IgG had enhanced recognition of G476S compared to purified IgA (not significant),  
254 which may suggest that IgG and IgA may recognize different epitopes for this mutant (fig. 3b,  
255 sup. fig. 5c). Importantly, for 22 of the 23 mutants (95.65%) there were marginal differences  
256 in ACE2 binding inhibition for purified IgG and IgA, suggesting that IgG and IgA can neutralise  
257 most RBD mutants similarly. Taken together, this data suggests that purified convalescent IgA  
258 and IgG have similar capacities to recognise most RBD mutations assayed here. Where  
259 significant differences were observed in IgG and IgA antibody recognition, ACE2 binding  
260 inhibition or neutralisation was marginally impacted.

261

## 262 **SARS-CoV-2 specific IgG mediates Fc effector function of convalescent plasma**

263 Antibody Fc portions can engage with FcγR on monocytes to mediate antibody dependent  
264 phagocytosis (ADP). Anti-SARS-CoV-2 IgG mAb's and plasma IgG has been reported to induce  
265 robust ADCP responses, however, the Fc functional role of plasma IgA in SARS-CoV-2 is yet to  
266 be characterised. Here, we investigated the capacity of convalescent plasma to induce ADP  
267 using a previously described SARS-CoV-2 ADP bead assay (W. S. Lee et al., 2021). We  
268 measured the antibody-mediated uptake of spike trimer (S)-conjugated fluorescent beads by  
269 THP-1 monocytes with a subset of convalescent (n=18) and uninfected control plasma (n=12)  
270 (fig. 4a). All convalescent subjects had higher ADP (median phagocytic score= $9.31 \times 10^3$  IQR=  
271  $7.14 \times 10^3 - 11.20 \times 10^3$ ), compared to uninfected subjects (median phagocytic score= $0.11 \times$   
272  $10^3$  IQR= $0 \times 10^3 - 0.45 \times 10^3$ ,  $p < 0.0001$ ) (fig. 4a). To determine the contribution of IgA and IgG  
273 to the ADP response against SARS-CoV-2, we measured ADP activity mediated by IgA- and  
274 IgA-/IgG- plasma. (fig. 4b). Depletion of IgA had no effect on the ADP capacity of the  
275 convalescent plasma (convalescent plasma: median phagocytic score= $9.31 \times 10^3$ ; IgA- plasma:  
276 median phagocytic score= $10.01 \times 10^3$  IQR=  $5.91 \times 10^3 - 12.98 \times 10^3$ ,  $p > 0.999$ ) (fig. 4b).  
277 Conversely, depletion of IgG (IgA-/IgG- plasma) (median= $2.20 \times 10^3$  IQR=  $1.36 \times 10^3 - 3.11 \times$   
278  $10^3$ ) resulted in a median loss of 76.37% ADP activity compared to convalescent plasma  
279 ( $p < 0.0001$ ) (fig. 4b). This data highlights the importance of the IgG antibody isotype in the Fc  
280 functional capacity of SARS-CoV-2 convalescent plasma.

281

282 In addition to uptake of antibody opsonised virions, antibodies can also mediate cell  
283 association and trogocytosis of infected cells expressing SARS-CoV-2 spike. Using an  
284 established cell association assay (W. S. Lee et al., 2021), we measured antibody mediated  
285 association of THP-1 monocytes with cells expressing SARS-CoV-2 spike (Ramos S-orange  
286 cells) following incubation with convalescent (n=18) and uninfected subject plasma (n=12)  
287 (fig.4c). Antibody mediated association was detected in all convalescent subjects (median  
288 association= $15.04\%$  association IQR=  $6.63\% - 27.66\%$ ) when compared to uninfected subjects  
289 (median association= $0.3\%$  association IQR=  $0.08\% - 0.53\%$ ,  $p < 0.0001$ ) (fig. 4c). We then  
290 investigated the contribution of IgA and IgG to cell association/ trogocytosis through  
291 depletion of IgA (IgA- plasma) and IgG (IgA-/IgG- depleted plasma) from convalescent plasma  
292 (fig. 4d). Depletion of IgA (median association= $10.02\%$  IQR= $6.50\% - 18.83\%$ ) did not

293 significantly alter the cell association mediated by convalescent plasma (median  
294 association=15.04% association IQR= 6.63%-27.66%,  $p>0.99$ ) (fig.4d). However, depletion of  
295 IgG (IgA-/IgG- plasma) (median association=1.33% association IQR=0.61%-3.10%) resulted in  
296 a median loss of 90.53% cell association relative to convalescent plasma (median  
297 association=15.04% association IQR= 6.63%-27.66%,  $p<0.0001$ ) (fig. 4d). This data further  
298 supports the role of IgG convalescent plasma for an effective Fc functional response to SARS-  
299 CoV-2.

300

### 301 **Discussion**

302 A strong correlate of protection for most viral vaccines, including SARS-CoV-2 vaccines, are  
303 neutralising antibodies (Khoury et al., 2021; Plotkin, 2010). IgM and IgG have been widely  
304 implicated in effective neutralisation of SARS-CoV-2 (Gasser et al., 2021; Lopez et al., 2021;  
305 Natarajan, Xu, et al., 2021; Wheatley et al., 2021). However, throughout the COVID-19  
306 pandemic, the study of anti-SARS-CoV-2 IgA responses have been relatively neglected  
307 (Verkerke et al., 2021). The plasma IgA response to SARS-CoV-2 peaks during acute infection  
308 but is relatively transient in nature, dominating the acute plasma neutralising response with  
309 a 2 phased decay in antibody binding to spike (half-life of 42 days in the first 60 days and  
310  $>1000$  days from 60-160 days post symptom onset) (Sterlin et al., 2021; Wheatley et al., 2021).  
311 Using our surrogate neutralisation assay, we show that anti-RBD plasma IgA present during  
312 early convalescence contributes to the neutralising capacity, in addition to IgG and IgM  
313 isotypes, for many individuals. As observed by Gasser et al., (2021), we also found decreased  
314 neutralisation when IgA was depleted from convalescent plasma, supporting IgA's  
315 contribution to SARS-CoV-2 neutralisation. Furthermore, for the first time we show that IgA  
316 depletion and IgG depletion also reduces neutralisation for several RBD mutations.

317

318 We observed IgA-associated and IgA-independent neutralising antibody responses within this  
319 convalescent cohort. An IgA-independent neutralising response was observed in 30.3% of  
320 individuals with no change in ACE2 binding inhibition when IgA was depleted. While 69.7% of  
321 this cohort showed a significant reduction in neutralisation when IgA was depleted,  
322 suggesting IgA contributes to neutralization within these individuals. Furthermore, similar to  
323 Wang et al., (2021) a subset of convalescent individuals mediated superior neutralisation with  
324 IgA when compared to IgG. However, purified IgG mediated higher RBD-ACE2 inhibition

325 compared to purified IgA for most convalescent donors. While IgG and IgA contribute to  
326 convalescent plasma neutralisation, depletion of IgG and IgA did not abolish neutralisation in  
327 many individuals, supporting the role of IgM in the convalescent plasma neutralising response  
328 to SARS-CoV-2 (Gasser et al., 2021; Natarajan, Xu, et al., 2021). Our data further supports the  
329 finding that IgA is capable of neutralising SARS-CoV-2 WT, although this response is  
330 heterogenous with in this cohort, likely due to heterogeneity in IgA titres against RBD.

331

332 This was confirmed by spiking increasing concentrations of purified IgA back into IgA- plasma,  
333 resulting in increased capacity for plasma to mediate SARS-CoV-2 neutralisation. IgA has been  
334 widely reported to be broadly cross reactive towards human coronaviruses, particularly in the  
335 elderly (Selva et al., 2021a). Therefore, it is also possible that pre-existing IgA+ memory B cells  
336 for human coronaviruses may recognise SARS-CoV-2 RBD with higher affinity and undergo  
337 somatic hypermutation to create a potent and robust IgA response in some individuals (Wec  
338 et al., 2020). Another possible explanation for the variability between individuals could be  
339 preferential class switching to IgG or IgA due to the cytokine environment and/or host  
340 genetics. Although, cytokine analysis or sequencing of gamma and alpha genes were not in  
341 the scope of this project, the cytokine profiles induced by SARS-CoV-2 vary with disease  
342 severity (Ghazavi et al., 2021) and may impact class switching (Cerutti, 2008; Stavnezer, 1996).

343

344 Intriguingly, we also observed a single individual which showed decreased neutralisation and  
345 IgM binding to RBDWT when increasing concentrations of purified IgA were spiked back into  
346 IgA- depleted plasma. This suggests IgA in rare cases may block RBD-specific IgM antibodies  
347 from binding and neutralising SARS-CoV-2. Similarly, HIV-1 vaccine induced IgA antibodies  
348 have previously been reported to block binding of IgG to a protective epitope and prevent  
349 neutralisation and effector functions (Tomaras et al., 2013). However, in most instances anti-  
350 SARS-CoV-2 convalescent IgA has the capacity to neutralise wild-type SARS-CoV-2 when  
351 sufficient titres of IgA are present.

352

353 As new variants of concern emerge consisting of a constellation of single amino acid  
354 substitutions within the RBD, it is important to understand antibody isotype (IgG and IgA)  
355 recognition and neutralising capacity to these single site mutations. Single amino acid  
356 substitutions can alter the stability and potentially the structure of the RBD, thus may reveal

357 or hide epitopes from different isotypes and/or subclasses of antibodies (Chowdhury et al.,  
358 2020; Verma & Subbarao, 2021). For individuals with IgA-skewed neutralisation, we  
359 compared the capacity for polyclonal purified convalescent IgA to recognise and neutralise  
360 single amino acid RBD mutants compared to IgG. We observed minor differences in purified  
361 antibody isotype binding to various RBD single mutants, despite the small sample sizes and  
362 the polyclonal nature of these convalescent responses. A trend toward preferential IgG  
363 binding to many mutants was observed, with significantly increased IgG binding to 5  
364 mutations. Interestingly, we observed a trend towards increased IgA binding to a single RBD  
365 mutation; G446V, which is predicted to reduce RBD stability and increase ACE2 affinity  
366 (Verma & Subbarao, 2021). The Fc portion of the antibody can affect the fine epitope  
367 specificity (binding affinity/epitope recognition) of the Fab region which could explain slight  
368 variation in IgG and IgA recognition of RBD mutants (Casadevall & Janda, 2012; Ejemel et al.,  
369 2020; Janda et al., 2012; Tudor et al., 2012). Furthermore, increased flexibility of the hinge of  
370 IgA1, the predominant subclass of IgA found in blood, may allow for increased accessibility to  
371 certain epitopes of Spike and RBD compared to IgG, such as the G446V mutation (Davis et al.,  
372 2020; Ejemel et al., 2020). Overall, our results show that convalescent IgG and IgA broadly  
373 recognise similar RBD epitopes with only minor differences in the ability to neutralise RBD  
374 mutants.

375  
376 In addition to antibody neutralisation, Fc effector functions such as phagocytosis, are  
377 important for control and clearance of SARS-CoV-2 infection (Butler et al., 2021; Chan et al.,  
378 2021; Winkler et al., 2021). Similar to previous studies, we show that convalescent plasma  
379 can mediate ADP (Butler et al., 2021, W. S. Lee et al., 2021). Interestingly, IgA depletion from  
380 convalescent plasma did not impact Fc effector functions by THP-1 monocytes. THP-1 cells  
381 express relatively low amounts of Fc $\alpha$ R, and thus we may not capture the functional potential  
382 of IgA that has been alluded to by Butler et al., (2021) who suggested convalescent IgA  
383 contributes to the functional capacity of convalescent plasma through regression analysis.  
384 Importantly, depletion of IgG abolished Fc effector functions in our assays, further reinforcing  
385 the importance of IgG in the polyfunctional (neutralising and Fc effector function) antibody  
386 response of convalescent plasma.

387

388 Overall, we find that convalescent plasma IgA recognises RBDWT and an array of RBD mutants  
389 and has the capacity to block ACE2 engagement with RBD in a comparable manner to IgG,  
390 when sufficient IgA titers are induced. Furthermore, the convalescent IgA neutralising  
391 response is highly heterogenous between individuals, with a third of the cohort inducing  
392 stronger IgA-mediated inhibition of RBD engagement with ACE2 than IgG, when tested at  
393 equivalent concentrations. Dissecting the IgA response in the context of vaccination and to  
394 variants of concern is essential to further understand the importance of IgA in a protective  
395 polyclonal antibody response.

396

## 397 **Materials and Methods**

### 398 Ethics statement

399 The study protocols were approved by the University of Melbourne Human Research Ethics  
400 Committee (#2056689) and all associated procedures were carried out in accordance with the  
401 approved guidelines. All participants provided written informed consent in accordance with  
402 the Declaration of Helsinki.

403

### 404 Human Subjects

405 Participants who had recovered from COVID-19 during the first wave of the pandemic in  
406 Melbourne, Australia, March-May 2020, were recruited as previously described (Wheatley et  
407 al., 2021). Convalescent subjects were confirmed to have had COVID-19 by returning a  
408 positive PCR test during early infection or had clear exposure to SARS-CoV-2 and tested  
409 positive for SARS-CoV-2 serology (both Spike trimer and RBD) confirming prior exposure as  
410 previously reported (Juno et al., 2020). Uninfected controls with no COVID-19 symptoms were  
411 also recruited during the first wave of COVID-19 and were confirmed as seronegative. Whole  
412 blood was collected with sodium heparin. The plasma fraction was then collected and stored  
413 at  $-80^{\circ}\text{C}$ . Cohort characteristics for convalescent and healthy controls are outlined in Table  
414 S1.

415

### 416 Human IgG and IgA ELISA

417 Purified IgG and IgA concentrations were quantified using human anti-IgG kit (cat# 3850-1AD-  
418 6 Mabtech) or anti-IgA kit (cat# 3860-1AD-6 Mabtech) respectively as per manufacturer's



419 instructions. Briefly, anti-IgG or IgA capture antibody was coated on Maxisorb 96 well plates  
420 (Nunc) overnight at 4°C. Plates were washed with PBS containing 0.05% Tween20 (PBST) and  
421 blocked with 1% BSA/PBST for 2 h. The plates were washed, and purified IgG or IgA antibodies  
422 were titrated 2-fold from 1:20,000 for a minimum of 4 points. To check for IgG contamination,  
423 purified IgA antibodies were tested at 1:1,000 and 1:2,000 dilutions. Similarly purified IgG  
424 antibodies were tested at 1:1,000 and 1:2,000 to check for IgA contamination. Antibodies and  
425 respective standards were incubated for 2h at RT before being washed. The secondary-ALP  
426 conjugated antibody was added to each well and incubated at RT for 1 h. The plate was  
427 washed, and the substrate p-nitrophenyl-phosphate (pNPP) was added and left to develop  
428 (~30mins). The optical density at 405nm was read using Thermo Fisher Multiskan Ascent plate  
429 reader. Purified IgA and IgG was confirmed to be free of contamination from the other isotype  
430 if their OD was less than the background no antibody OD plus 2 standard deviations.

431

432 Antibody purification and depletion

433 IgA purification and depletion from plasma samples were performed via affinity  
434 chromatography using peptide M agarose following manufacturer's instructions (sup. fig. 3a).  
435 Briefly, peptide M agarose (Jomar) was added to 1ml filter columns (thermofisher) and  
436 washed 3 times with PBS. 300ul of plasma was incubated with peptide M columns for 45  
437 minutes on an orbital at room temperature. Depleted IgA plasma fractions were collected by  
438 spinning at 1000g for 1 min after incubation. Purified IgA was eluted with low pH (pH2.8) by  
439 IgG Elution Buffer (Thermofisher). Elution was neutralised using Tris M pH 8.0 (Life Sciences).

440

441 IgG was purified from 100ul of IgA depleted (IgA-) plasma using 96 well Protein G HP MultiTrap  
442 (GE Healthcare) following manufacturer's instructions (sup. fig. 3a & b). Purified IgA was also  
443 passed through the MultiTrap to remove any IgG contamination. Briefly, IgA- plasma and  
444 purified IgA was diluted 1:1 in antibody binding buffer and added to the MultiTrap. Samples  
445 were incubated for 30 mins at RT while shaking. The plate was centrifuged, IgA and IgG (IgA-  
446 /IgG-) depleted plasma and purified IgA was collected. The plate was washed with antibody  
447 binding buffer before elution of IgG with 200ul of elution buffer (GE Healthcare). Purified IgG  
448 was collected via centrifugation at 200xg for 2 mins and neutralised to pH 7 using  
449 neutralisation buffer (GE Healthcare). Elution was performed 3 times and purified IgG, IgA-



450 and IgA-/IgG- plasma was buffer exchanged into PBS and concentrated to original starting  
451 volume.

452

#### 453 SARS-CoV-2 bead-based multiplex assay

454 The SARS-CoV-2 specific antibody isotypes (IgM, IgG and IgA1) were assessed using a  
455 multiplex assay as previously described (Selva et al., 2021). Briefly, bead mixture containing  
456 700 beads per bead region and diluted plasma or purified antibody, was added to each well  
457 in a black clear bottom 384 well plate. Phycoerythrin (PE)-conjugated mouse anti-human pan-  
458 IgG and IgA1 (Southern Biotech) (1.3µg/ml) were added to detect SARS-CoV-2 specific  
459 antibodies. For IgM detection, biotinylated mouse anti-human IgM (mAb MT22; MabTech)  
460 was added at 1.3 µg/ml. Following incubation, streptavidin R-Phycoerythrin conjugate (SAPE,  
461 Invitrogen) at 1 µg/ml was added. The plate was read via the FlexMap 3D and binding of PE-  
462 detectors was measured to calculate the median fluorescence intensity (MFI). Background  
463 was corrected for by subtracting the MFI of BSA-blocked beads for each well. Titrations of  
464 pooled convalescent plasma and an anti-SARS-CoV-2 RBD neutralising human IgG1 antibody  
465 (SAD-S35, ACRO Biosystems, USA) were included as positive controls and uninfected subject  
466 plasma was included as negative controls. A single dilution was used for plasma, depleted  
467 plasma and EC<sub>50</sub>'s were calculated for purified IgG and IgA where appropriate using  
468 normalised antibody binding.

469

#### 470 RBD-ACE2 binding inhibition multiplex bead-based assay

471 RBD-ACE2 binding inhibition assay was performed as previously described (Lopez et al., 2021).  
472 Briefly, an array of SARS-CoV-2 antigens including S1 (Sino Biological), RBD wild-type (WT) (B;  
473 wild-type, Wuhan) and 18 RBD single mutants used in figure 3a with 5 additional RBD mutants  
474 were included in figure 3b-e, in a bead suspension containing 700 beads per bead region were  
475 added to each well (20ul), with biotinylated Avitag-ACE2 (kindly provided by Dale Godfrey,  
476 Nicholas Gherardin and Samuel Redmond) at a final concentration of 12.5µg/ml per well, and  
477 dilutions of plasma or purified antibodies were added to 384-well plates. Biotinylated Avitag-  
478 ACE2 was detected using SAPE at 4µg/ml followed by PE-Biotin amplifier (Thermo Fisher) at  
479 10µg/ml. Plates were washed and acquired on a FlexMap 3D (Luminex). Anti-SARS-CoV-2 RBD  
480 neutralising human IgG1 antibody (SAD-S35, ACRO Biosystems, USA) was included as a  
481 positive control, in addition to COVID-19 negative plasma and buffer only negative controls.

482 The MFI of bound ACE2 was measured after background subtraction of no ACE2 controls.  
483 Maximal ACE2 binding MFI was determined by ACE2 only controls. % ACE2 binding inhibition  
484 was calculated as  $100\% - (\% \text{ ACE2 binding MFI per sample} / \text{Maximal ACE2 binding})$ .

485

486 Matching dilutions to account for loss of antibody during depletion process

487 Anti-RBDWT IgM (sup. fig. 3c) and IgG (sup. fig. 3d) binding was also assessed for plasma, IgA-  
488 and IgA-/IgG- depleted plasma via multiplex. During the depletion process, a loss of 48.88%  
489 of IgG (sup. fig. 3c, median MFI=21150,  $p=0.0160$ ) and 36.95% of IgM (sup. fig. 3d, median  
490 MFI=26544,  $p=0.0002$ ) between medians was observed following the depletion of IgA (IgA-  
491 plasma) and IgG (IgA-/IgG- plasma) respectively compared to plasma (median IgG MFI=41377,  
492 median IgM MFI=42101) (sup. fig. 3c-d). To ensure fair comparisons between plasma and  
493 depleted plasma fractions, plasma and depleted plasma samples were titrated, and anti-  
494 RBDWT IgG and IgM binding MFI was determined via multiplex (process outlined in sup. fig.  
495 3e). IgA- and IgA-/IgG- depleted plasma dilutions were chosen by matching IgG or IgM MFI  
496 respectively to plasma IgG or IgM binding MFI at a dilution of 1:100. IgA- plasma and IgA-/IgG-  
497 depleted plasma with final dilutions outlined in sup. table 2. These dilutions were used for all  
498 multiplex assays. Depleted samples with >30% loss in IgG or IgM following matching of  
499 dilutions were excluded from this study (sup. fig. 3b).

500

501 Quality control testing of antibody depleted plasma

502 Successful depletion IgG and IgA was confirmed for matched dilutions via IgG SARS-CoV-2  
503 RBDWT multiplex (sup. fig. 3f-k, sup. table 2). This method detected the remaining antigen  
504 specific IgG or IgA with high sensitivity which allowed for application of a stringent threshold  
505 for exclusion of samples with un-successful IgG or IgA depletion. Anti-RBDWT IgG or IgA  
506 binding MFI of depleted plasma was compared to full plasma for each subject and the  
507 percentage reduction in IgG and IgA binding was calculated. Sufficient depletion was defined  
508 as >70% depletion of IgG or IgA (i.e. >70% reduction in anti-RBDWT IgG MFI compared to  
509 plasma IgG MFI) (sup. fig. 3f-k). Plasma, IgA- plasma and IgA-/IgG- depleted plasma samples  
510 with <70% IgA or IgG depletion in were all excluded from this study (sup. fig. 3b). Only subjects  
511 with all three plasma fractions (plasma, IgA- and IgA-/IgG depleted ) were included in final  
512 analysis ( $n=30$ ) (sup. fig. 3b).

513

514 IgA spiking assay

515 Using RBDWT-ACE2 binding inhibition assay and the SARS-CoV-2 multiplex assay, purified IgA  
516 was spiked back into IgA- plasma up to 100µg/ml of IgA (12.5, 50 and 100µg/ml) as proof of  
517 concept that IgA contributes to ACE2 binding inhibition of convalescent plasma in a dose  
518 dependent manor.

519

520 Fc effector functional assays

521 *Cell culturing*

522 THP-1 monocytes (ATCC) and Ramos cells expressing mOrange2 SARS-CoV-2 spike trimer  
523 (Ramos S-orange cells) (W. S. Lee et al., 2021) were cultured in RPMI 1640 with 10% FCS  
524 (RF10) under recommended cell culture conditions (37°C with 5% carbon dioxide (CO<sub>2</sub>)). THP-  
525 1 monocytes and Ramos S-orange cells were maintained below a cell density of 0.3 x 10<sup>4</sup> and  
526 1.0 x 10<sup>4</sup> respectively. Flow cytometry was used to confirm stable expression of FcγRII (CD32),  
527 FcγRI (CD64) and FcαR (CD89) on THP-1 monocytes and stable expression of SARS-CoV-2 spike  
528 trimer (S-trimer) and expression of mOrange2 for Ramos S-orange cells. Cell viability was  
529 determined using trypan blue exclusion and morphology confirmed using light microscopy  
530 prior to assay preparation.

531

532 *Antibody dependent bead-based phagocytosis assay*

533 Antibody dependent bead-based phagocytosis assay was used as previously described (W. S.  
534 Lee et al., 2021). Briefly, SARS-CoV-2 spike trimer protein (S-trimer) (supplied by Adam  
535 Wheatly, The Peter Doherty Institute) was biotinylated and coupled to 1µm fluorescent  
536 NeutrAvidin Fluospheres (beads) (Invitrogen) overnight at 4°C. S-trimer coated beads were  
537 washed and diluted 1:100 in 2% BSA/PBS. 10ul of diluted S-trimer coated beads were  
538 incubated with plasma diluted 1:100 for 2 hours at 37°C in a 96 well U bottom cell culture  
539 plate. 10<sup>4</sup> THP-1 monocytes were added to opsonized beads and incubated for 16 hours under  
540 cell culturing conditions. THP-1 monocytes were fixed, and cells were acquired by flow  
541 cytometry on a BD LSR Fortessa with a HTS (sup. fig. 6a for gating strategy). The data was  
542 analysed using FlowJo 10.7.1 and a phagocytosis score ([% bead positive cells x mean  
543 fluorescent intensity]/ 10<sup>3</sup>) was calculated as previously described Darrah, Patel et al. (2007).

544

#### 545 *THP-1 and Ramos S-orange cell association assay*

546 A THP-1 and Ramos S-orange cell association was used as previously described (W. S. Lee et  
547 al., 2021). Briefly, THP-1 monocytes were stained with CellTrace™ Violet (CTV) (Life  
548 Technologies) as per manufacturer's instructions. Concurrently,  $10^4$  Ramos S-orange cells  
549 were added to each well in a 96-well V bottom cell culture plate. Plasma was diluted to 1:900  
550 with the Ramos S-orange cells and incubated for 30 minutes under cell culture conditions.  
551 Oponised Ramos S-orange cells were washed by centrifugation and  $10^4$  of CTV stained THP-  
552 1 monocytes were added for a final 1:1 ratio of THP-1 monocytes to Ramos S-orange cells.  
553 Oponised Ramos S-orange cells and THP-1 monocytes were incubated for 1 hour under cell  
554 culture conditions before fixation. Cells were acquired by flow cytometry using the BD LSR  
555 Fortessa with a high-throughput sampler attachment (HTS) and the data was analysed using  
556 FlowJo 10.7.1 (sup. fig. 6b for gating strategy). The percentage of Ramos S-orange cells  
557 associated with THP-1 monocytes (% association) was extracted.

558

#### 559 Data normalisation

560 For purified antibody binding to the RBD single mutants of subjects with IgA neutralisation  
561 (n=13), antibody MFI values were normalised to the maximum antibody binding (100%) (IgG  
562 and IgA) to each variant to account for differences in coupling efficiency for the RBD mutants.  
563 The normalised purified antibody binding was used to calculate  $EC_{50}$ 's for purified IgG and IgA.  
564  $EC_{50}$ 's >400 were set to the threshold of 400.

565

#### 566 Data analysis

567 Traditional statistical analyses were performed with Graphpad Prism 9. See figure legends  
568 for details. Partial Least Squares Regression Analyses were conducted to determine  
569 multivariate relationships between immune features and continuous variables (e.g. ACE2  
570 binding inhibition) using Matlab with the statistics and machine learning toolbox  
571 (Mathworks) and PLS\_Toolbox (Eigenvector).

572

#### 573 **Acknowledgments**

574 This study was supported by the Medical Research Future Fund (MRFF) (W.-H.T.,  
575 D.I.G., A.W.C., S.J.K., A.K.W. and J.A.J ), Emergent Ventures Fast Grant (A.W.C.)  
576 and the Paul Ramsay Foundation (D.I.G., S.J.K., A.K.W and A.W.C). A.K.W., J.A.J,  
577 D.I.G., W.-H.T., S.J.K., and A.W.C are supported by NHMRC fellowships. W-H.T. is a  
578 Howard Hughes Medical Institute–Wellcome Trust International Research Scholar  
579 (208693/Z/17/Z). N.A.G. is supported by an ARC DECRA fellowship.

580

## 581 **Figure Legends**

### 582 **Figure 1. Convalescent plasma induced robust anti-SARS-CoV-2 RBDWT antibody isotypes** 583 **levels that inhibit ACE2 from binding RBDWT**

584 Convalescent (n=41) (blue) and uninfected control (n=26) (grey) plasma (final dilution 1:100)  
585 was assessed for IgM **(a)**, IgG **(b)** and IgA **(c)** antibody binding to SARS-CoV-2 RBDWT via  
586 multiplex. A positive threshold (grey dotted line) was defined as the 75<sup>th</sup> percentile of  
587 antibody binding (MFI) for uninfected control plasma to respective antigens. **(d)** RBDWT ACE2  
588 binding inhibition (%) of convalescent (blue) and uninfected control (grey) plasma (diluted  
589 1:100). A positive threshold (grey dotted line) was defined as >20% ACE2 binding inhibition.  
590 **(e)** Pie chart outlining the percentage of subjects seropositive for anti-RBDWT antibody  
591 isotypes (IgM-IgG+IgA+ (green), IgM+IgG+IgA+ (blue), IgM+IgG+IgA- (yellow)) in the inner ring  
592 and the percentage of each seropositive subset with ACE2 binding inhibition in the outer red  
593 ring. Partial Least Squares Regression (PLSR) were conducted to determine the multivariate  
594 relationship between anti-RBD-specific isotype antibodies (IgG, IgA, and IgM) and % RBDWT-  
595 ACE2 binding inhibition (% ACE2 binding inhibition illustrated as a colour gradient legend on  
596 the right- yellow-strongest to dark blue- weakest). PLSR Scores **(f)** and loadings plot **(g)**.  
597 Percent variance for each latent variable (LV) in parentheses.

598

### 599 **Figure 2. IgA from convalescent plasma induces variable levels of % RBD-ACE2 binding** 600 **inhibition.**

601 SARS-CoV-2 RBDWT ACE2 binding inhibition (%) of **(a)** convalescent plasma (diluted 1:200;  
602 blue) and matched dilutions of IgA depleted (IgA-; yellow) and IgA plus IgG depleted (IgA-/IgG-  
603 ; purple) (n=30) plasma fractions. Comparisons between plasma and depleted fractions was  
604 conducted using Friedman with Dunn's multiple comparison test. (sup. Fig. 3 describes  
605 inclusion/exclusion criteria for successful antibody depletion); Comparison of matched

606 purified IgG (green) and IgA (blue) RBDWT ACE2 binding inhibition tested at 100µg/ml total  
607 purified antibody separated as individuals where **(b)** purified IgG or **(c)** purified IgA mediated  
608 enhanced ACE2 binding inhibition. **(d)** Correlation (non-parametric Spearman test) between  
609 RBDWT-ACE2 binding inhibition (%) and anti-RBDWT antibody IgG and IgA isotype binding  
610 (MFI) tested at 100µg/ml total antibody. **(e)** RBDWT IgA binding (MFI) and **(f)** ACE2 binding  
611 inhibition (%) were assessed as increasing concentrations (yellow, 0, 12.5, 50 and 100µg/ml  
612 total antibody) of purified COVID+ IgA was spiked back into IgA depleted plasma (n=3). While  
613 **(g)** samples where IgA depletion resulted in an increase in RBDWT ACE2 binding inhibition **(h)**  
614 anti-RBDWT antibody IgG, IgA and IgM isotype binding (MFI) and **(i)** ACE2 binding inhibition  
615 (%) were assessed as increasing concentrations of purified IgA were spiked back into  
616 respective IgA- depleted plasma for this individual.

617

618 **Figure 3. Similar antibody binding and ACE2 binding inhibition of convalescent purified IgA**  
619 **to RBD single mutants compared to IgG**

620 **(a)** Heatmap of the mean ACE2 binding inhibition (%) for RBDWT and 18 RBD single mutants  
621 of matched complete plasma, IgA- depleted , and IgA-/IgG- depleted plasma (n=30). Purified  
622 IgA (blue) and IgG (green) **(b)** fold change in antibody EC<sub>50</sub> binding relative to RBDWT for 23  
623 different RBD single mutants of subjects (n=13) **(c)** Fold change in RBD-ACE2 binding inhibition  
624 relative to RBDWT for 23 different RBD single mutants of subjects for the same samples  
625 (n=13). Statistical analyses were performed with the Paired t test adjusting for multiple  
626 comparisons using the Holm-Šídák method (\*=p<0.05, \*\*=p<0.01). The median fold change  
627 in **(d)** antibody EC<sub>50</sub> binding and **(e)** % RBD-ACE2 binding inhibition relative to RBDWT for each  
628 RBD mutant is summarized as heatmaps.

629

630 **Figure 4. Depletion of IgG but not IgA reduces the Fc functional capacity of convalescent**  
631 **plasma**

632 **(a)** Antibody dependent phagocytosis (ADP) of S-conjugated beads for a subset of  
633 convalescent subject plasma (blue) (n=18) and uninfected control plasma (grey) (n=12)  
634 (diluted 1:900). **(b)** Comparison of ADP of S-conjugated beads from matched convalescent  
635 subject plasma (blue), IgA depleted plasma (IgA-; yellow) and IgA and IgG depleted plasma  
636 (IgA-/IgG-; purple) (n=18). **(c)** Fcγ Receptor (FcγR) dependent association of THP-1 cells with  
637 Ramos S-orange cells mediated by convalescent plasma (blue) and uninfected control plasma

638 (grey) (diluted 1:100). **(d)** FcyR dependent association of THP-1 cells with Ramos S-orange  
639 cells from matched convalescent subject plasma (blue), IgA depleted plasma (IgA-; yellow)  
640 and IgA and IgG depleted plasma (IgA-/IgG-; purple) (n=18). Grey dotted lines denote the  
641 negative threshold for cell association (<2%) and ADP ( $3 \times 10^3$ ) calculated as the mean  
642 response of negative subject plasma plus 2 standard deviations. Statistical analyses were  
643 performed with the Kruskal-Wallis test followed by Dunn's multiple comparisons test.  
644  
645



## 646 References

647

- 648 Asokan, M., Diasb, J., Liu, C., Maximovaa, A., Ernste, K., Pegu, A., McKee, K., Shi, W., Chen,  
649 X., Almasri, C., Promsote, W., Ambrozak, D. R., Gama, L., Hu, J., Douek, D. C., Todd, J. P.,  
650 Lifson, J. D., Fourati, S., Sekaly, R. P., ... Koup, R. A. (2020). Fc-mediated effector  
651 function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.  
652 *Proceedings of the National Academy of Sciences of the United States of America*,  
653 *117*(31), 18754–18763. [https://doi.org/10.1073/PNAS.2008236117/-](https://doi.org/10.1073/PNAS.2008236117/-/DCSUPPLEMENTAL)  
654 [/DCSUPPLEMENTAL](https://doi.org/10.1073/PNAS.2008236117/-/DCSUPPLEMENTAL)
- 655 Blutt, S. E., Miller, A. D., Salmon, S. L., Metzger, D. W., & Conner, M. E. (2012). IgA is  
656 Important for Clearance and Critical for Protection from Rotavirus Infection. *Mucosal*  
657 *Immunology*, *5*(6), 712. <https://doi.org/10.1038/MI.2012.51>
- 658 Brown, E. P., Licht, A. F., Dugast, A. S., Choi, I., Bailey-Kellogg, C., Alter, G., & Ackerman, M.  
659 E. (2012). High-throughput, multiplexed IgG subclassing of antigen-specific antibodies  
660 from clinical samples. *Journal of Immunological Methods*, *386*(1–2), 117–123.  
661 <https://doi.org/10.1016/J.JIM.2012.09.007>
- 662 Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E.,  
663 Lee, J., Wieland-Alter, W., Connor, R. I., Wright, P. F., & Ackerman, M. E. (2021).  
664 Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among  
665 SARS-CoV-2 Convalescent Individuals. *Frontiers in Immunology*, *11*, 3797.  
666 <https://doi.org/10.3389/FIMMU.2020.618685/BIBTEX>
- 667 Casadevall, A., & Janda, A. (2012). Immunoglobulin isotype influences affinity and specificity.  
668 *Proceedings of the National Academy of Sciences*, *109*(31), 12272–12273.  
669 <https://doi.org/10.1073/PNAS.1209750109>
- 670 Cerutti, A. (2008). The regulation of IgA class switching. *Nature Reviews Immunology* *2008*  
671 *8:6*, *8*(6), 421–434. <https://doi.org/10.1038/nri2322>
- 672 Chan, C. E. Z., Seah, S. G. K., Chye, D. H., Massey, S., Torres, M., Lim, A. P. C., Wong, S. K. K.,  
673 Neo, J. J. Y., Wong, P. S., Lim, J. H., Loh, G. S. L., Wang, D., Boyd-Kirkup, J. D., Guan, S.,  
674 Thakkar, D., Teo, G. H., Purushotorman, K., Hutchinson, P. E., Young, B. E., ... Hanson, B.  
675 J. (2021). The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing  
676 antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for  
677 the optimal therapeutic efficacy of the antibody. *PLOS ONE*, *16*(6), e0253487.  
678 <https://doi.org/10.1371/JOURNAL.PONE.0253487>
- 679 Choi, J. Y., & Smith, D. M. (2021). SARS-CoV-2 Variants of Concern. *Yonsei Medical Journal*,  
680 *62*(11), 961. <https://doi.org/10.3349/YMJ.2021.62.11.961>
- 681 Chowdhury, R., Boorla, V. S., & Maranas, C. D. (2020). Computational biophysical  
682 characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and  
683 implications for infectivity. *Computational and Structural Biotechnology Journal*, *18*,  
684 2573–2582. <https://doi.org/10.1016/J.CSBJ.2020.09.019>
- 685 Collier, A. Y., Yu, J., McMahan, K., Liu, J., Chandrashekar, A., Maron, J. S., Atyeo, C., Martinez,  
686 D. R., Ansel, J. L., Aguayo, R., Rowe, M., Jacob-Dolan, C., Sellers, D., Barrett, J., Ahmad,  
687 K., Anioke, T., VanWyk, H., Gardner, S., Powers, O., ... Barouch, D. H. (2021). Differential  
688 Kinetics of Immune Responses Elicited by Covid-19 Vaccines. *New England Journal of*  
689 *Medicine*, *385*(21), 2010–2012.  
690 [https://doi.org/10.1056/NEJMC2115596/SUPPL\\_FILE/NEJMC2115596\\_DISCLOSURES.P](https://doi.org/10.1056/NEJMC2115596/SUPPL_FILE/NEJMC2115596_DISCLOSURES.PDF)  
691 [DF](https://doi.org/10.1056/NEJMC2115596/SUPPL_FILE/NEJMC2115596_DISCLOSURES.PDF)

- 692 Davis, S. K., Selva, K. J., Kent, S. J., & Chung, A. W. (2020). Serum IgA Fc effector functions in  
693 infectious disease and cancer. *Immunology and Cell Biology*, *98*(4), 276–286.  
694 <https://doi.org/10.1111/IMCB.12306>
- 695 Devarasetti, P. K., Rajasekhar, L., Baisya, R., Sreejitha, K. S., & Vardhan, Y. K. (2021). A review  
696 of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.  
697 *Immunologic Research* *2021 69:1*, *69*(1), 18–25. [https://doi.org/10.1007/S12026-020-  
698 \*09169-X\*](https://doi.org/10.1007/S12026-020-09169-X)
- 699 Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann,  
700 A., Planchais, C., Buchrieser, J., Robinot, R., Ungeheuer, M. N., Mouquet, H., Charneau,  
701 P., White, M., Lévy, Y., Hoen, B., Fontanet, A., Schwartz, O., & Bruel, T. (2021).  
702 Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.  
703 *Cell Reports Medicine*, *2*(5), 100275. <https://doi.org/10.1016/J.XCRM.2021.100275>
- 704 Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A.,  
705 Hallett, S. R., Pickering, S., Charalampous, T., Alcolea-Medina, A., Huettner, I., Jimenez-  
706 Guardado, J. M., Acors, S., Almeida, N., Cox, D., Dickenson, R. E., Galao, R. P., Kouphou,  
707 N., ... Doores, K. J. (2021). Neutralizing antibody activity in convalescent sera from  
708 infection in humans with SARS-CoV-2 and variants of concern. *Nature Microbiology*  
709 *2021 6:11*, *6*(11), 1433–1442. <https://doi.org/10.1038/s41564-021-00974-0>
- 710 Ejemel, M., Li, Q., Hou, S., Schiller, Z. A., Tree, J. A., Wallace, A., Amcheslavsky, A., Kurt  
711 Yilmaz, N., Buttigieg, K. R., Elmore, M. J., Godwin, K., Coombes, N., Toomey, J. R.,  
712 Schneider, R., Ramchetty, A. S., Close, B. J., Chen, D.-Y., Conway, H. L., Saeed, M., ...  
713 Wang, Y. (2020). A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2  
714 spike-ACE2 interaction. *Nature Communications* *2020 11:1*, *11*(1), 1–9.  
715 <https://doi.org/10.1038/s41467-020-18058-8>
- 716 Falsey, A. R., Frenck, R. W., Walsh, E. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.,  
717 Bailey, R., Swanson, K. A., Xu, X., Koury, K., Kalina, W., Cooper, D., Zou, J., Xie, X., Xia,  
718 H., Türeci, Ö., Lagkadinou, E., Tompkins, K. R., ... Gruber, W. C. (2021). SARS-CoV-2  
719 Neutralization with BNT162b2 Vaccine Dose 3. *New England Journal of Medicine*,  
720 *385*(17), 1627–1629.  
721 [https://doi.org/10.1056/NEJMC2113468/SUPPL\\_FILE/NEJMC2113468-](https://doi.org/10.1056/NEJMC2113468/SUPPL_FILE/NEJMC2113468_DISCLOSURES.PDF)  
722 [DISCLOSURES.PDF](https://doi.org/10.1056/NEJMC2113468/SUPPL_FILE/NEJMC2113468_DISCLOSURES.PDF)
- 723 Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser,  
724 B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G., Charles, R.  
725 C., Dighe, A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G., Iafrate, A. J., &  
726 Balazs, A. B. (2021). COVID-19-neutralizing antibodies predict disease severity and  
727 survival. *Cell*, *184*(2), 476-488.e11. <https://doi.org/10.1016/J.CELL.2020.12.015>
- 728 Gasser, R., Cloutier, M., Prévost, J., Fink, C., Ducas, É., Ding, S., Dussault, N., Landry, P.,  
729 Tremblay, T., Laforce-Lavoie, A., Lewin, A., Beaudoin-Bussièrès, G., Laumaea, A.,  
730 Medjahed, H., Larochelle, C., Richard, J., Dekaban, G. A., Dikeakos, J. D., Bazin, R., &  
731 Finzi, A. (2021). Major role of IgM in the neutralizing activity of convalescent plasma  
732 against SARS-CoV-2. *Cell Reports*, *34*(9), 108790.  
733 <https://doi.org/10.1016/J.CELREP.2021.108790>
- 734 Ghazavi, A., Ganji, A., Keshavarzian, N., Rabiemajd, S., & Mosayebi, G. (2021). Cytokine  
735 profile and disease severity in patients with COVID-19. *Cytokine*, *137*, 155323.  
736 <https://doi.org/10.1016/J.CYTO.2020.155323>
- 737 Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M.,  
738 Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium,

- 739 Peacock, S. J., & Robertson, D. L. (2021). SARS-CoV-2 variants, spike mutations and  
740 immune escape. *Nature Reviews. Microbiology*, 1–16. [https://doi.org/10.1038/s41579-](https://doi.org/10.1038/s41579-021-00573-0)  
741 [021-00573-0](https://doi.org/10.1038/s41579-021-00573-0)
- 742 Janda, A., Eryilmaz, E., Nakouzi, A., Cowburn, D., & Casadevall, A. (2012). Variable Region  
743 Identical Immunoglobulins Differing in Isotype Express Different Paratopes \*. *Journal of*  
744 *Biological Chemistry*, 287(42), 35409–35417.  
745 <https://doi.org/10.1074/JBC.M112.404483>
- 746 Juno, J. A., Tan, H.-X., Lee, W. S., Reynaldi, A., Kelly, H. G., Wragg, K., Esterbauer, R., Kent, H.  
747 E., Batten, C. J., Mordant, F. L., Gherardin, N. A., Pymm, P., Dietrich, M. H., Scott, N. E.,  
748 Tham, W.-H., Godfrey, D. I., Subbarao, K., Davenport, M. P., Kent, S. J., & Wheatley, A.  
749 K. (2020). Humoral and circulating follicular helper T cell responses in recovered  
750 patients with COVID-19. *Nature Medicine* 2020 26:9, 26(9), 1428–1434.  
751 <https://doi.org/10.1038/s41591-020-0995-0>
- 752 Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao,  
753 K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are  
754 highly predictive of immune protection from symptomatic SARS-CoV-2 infection.  
755 *Nature Medicine* 2021 27:7, 27(7), 1205–1211. [https://doi.org/10.1038/s41591-021-](https://doi.org/10.1038/s41591-021-01377-8)  
756 [01377-8](https://doi.org/10.1038/s41591-021-01377-8)
- 757 Klingler, J., Weiss, S., Itri, V., Liu, X., Oguntuyo, K. Y., Stevens, C., Ikegame, S., Hung, C.-T.,  
758 Enyindah-Asonye, G., Amanat, F., Baine, I., Arinsburg, S., Bandres, J. C., Kojic, E. M.,  
759 Stoeber, J., Jurczynszak, D., Bermudez-Gonzalez, M., Simon, V., Nádas, A., ... Hioe, C. E.  
760 (2020). Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *MedRxiv :*  
761 *The Preprint Server for Health Sciences*. <https://doi.org/10.1101/2020.08.18.20177303>
- 762 Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G.,  
763 Haycroft, E. R., Tan, H. X., Juno, J. A., Wheatley, A. K., Hogarth, P. M., Cromer, D.,  
764 Davenport, M. P., Chung, A. W., & Kent, S. J. (2021). Decay of Fc-dependent antibody  
765 functions after mild to moderate COVID-19. *Cell Reports Medicine*, 2(6), 100296.  
766 <https://doi.org/10.1016/J.XCRM.2021.100296>
- 767 Lee, W. T., Girardin, R. C., Dupuis, A. P., Kulas, K. E., Payne, A. F., Wong, S. J., Arinsburg, S.,  
768 Nguyen, F. T., Mendu, D. R., Firpo-Betancourt, A., Jhang, J., Wajnberg, A., Krammer, F.,  
769 Cordon-Cardo, C., Amler, S., Montecalvo, M., Hutton, B., Taylor, J., & McDonough, K. A.  
770 (2021). Neutralizing Antibody Responses in COVID-19 Convalescent Sera. *The Journal of*  
771 *Infectious Diseases*, 223(1), 47–55. <https://doi.org/10.1093/INFDIS/JIAA673>
- 772 Liu, X., Wang, J., Xu, X., Liao, G., Chen, Y., & Hu, C.-H. (2020). Patterns of IgG and IgM  
773 antibody response in COVID-19 patients.  
774 [Htts://Doi.Org/10.1080/22221751.2020.1773324](https://doi.org/10.1080/22221751.2020.1773324), 9(1), 1269–1274.  
775 <https://doi.org/10.1080/22221751.2020.1773324>
- 776 Lopez, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J.,  
777 Lee, W. S., Gherardin, N. A., Wheatley, A. K., Juno, J. A., Selva, K. J., Davis, S. K., Grimley,  
778 S. L., Harty, L., Purcell, D. F. J., Subbarao, K., Godfrey, D. I., Kent, S. J., ... Chung, A. W.  
779 (2021). Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via  
780 multiplex assay. *JCI Insight*. <https://doi.org/10.1172/JCI.INSIGHT.150012>
- 781 Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V.,  
782 Mandelboim, M., Doolman, R., Amit, S., Mendelson, E., Ziv, A., Huppert, A., Rubin, C.,  
783 Freedman, L., & Kreiss, Y. (2021). BNT162b2 COVID-19 vaccine and correlates of  
784 humoral immune responses and dynamics: a prospective, single-centre, longitudinal

- 785 cohort study in health-care workers. *The Lancet. Respiratory Medicine*, 9(9), 999.  
786 [https://doi.org/10.1016/S2213-2600\(21\)00220-4](https://doi.org/10.1016/S2213-2600(21)00220-4)
- 787 Maeda, K., Higashi-Kuwata, N., Kinoshita, N., Kutsuna, S., Tsuchiya, K., Hattori, S., Matsuda,  
788 K., Takamatsu, Y., Gatanaga, H., Oka, S., Sugiyama, H., Ohmagari, N., & Mitsuya, H.  
789 (2021). Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.  
790 *Scientific Reports 2021 11:1*, 11(1), 1–12. <https://doi.org/10.1038/s41598-021-84733-5>
- 791 Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K.,  
792 Wieland-Alter, W., Connor, R. I., Wright, P. F., Benner, S. E., Bonny, T. S., Laeyendecker,  
793 O., Sullivan, D., Shoham, S., Quinn, T. C., Larman, H. B., Casadevall, A., Pekosz, A., ...  
794 Ackerman, M. E. (2021a). Markers of polyfunctional sars-cov-2 antibodies in  
795 convalescent plasma. *MBio*, 12(2). [https://doi.org/10.1128/MBIO.00765-](https://doi.org/10.1128/MBIO.00765-21/SUPPL_FILE/MBIO.00765-21-ST003.PDF)  
796 [21/SUPPL\\_FILE/MBIO.00765-21-ST003.PDF](https://doi.org/10.1128/MBIO.00765-21/SUPPL_FILE/MBIO.00765-21-ST003.PDF)
- 797 Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K.,  
798 Wieland-Alter, W., Connor, R. I., Wright, P. F., Benner, S. E., Bonny, T. S., Laeyendecker,  
799 O., Sullivan, D., Shoham, S., Quinn, T. C., Larman, H. B., Casadevall, A., Pekosz, A., ...  
800 Ackerman, M. E. (2021b). Markers of polyfunctional sars-cov-2 antibodies in  
801 convalescent plasma. *MBio*, 12(2). <https://doi.org/10.1128/MBIO.00765-21>
- 802 Natarajan, H., Xu, S., Crowley, A. R., Butler, S. E., Weiner, J. A., Bloch, E. M., Littlefield, K.,  
803 Benner, S. E., Shrestha, R., Ajayi, O., Wieland-Alter, W., Sullivan, D., Shoham, S., Quinn,  
804 T. C., Casadevall, A., Pekosz, A., Redd, A. D., Tobian, A. A. R., Connor, R. I., ... Ackerman,  
805 M. E. (2021). Antibody Attributes that Predict the Neutralization and Effector Function  
806 of Polyclonal Responses to SARS-CoV-2. *MedRxiv*.  
807 <https://doi.org/10.1101/2021.08.06.21261710>
- 808 Plotkin, S. A. (2010). Correlates of Protection Induced by Vaccination. *Clinical and Vaccine*  
809 *Immunology*, 17(7), 1055–1065. <https://doi.org/10.1128/CVI.00131-10>
- 810 Rössler, A., Riepler, L., Bante, D., Laer, D. von, & Kimpel, J. (2021). SARS-CoV-2 B.1.1.529  
811 variant (Omicron) evades neutralization by sera from vaccinated and convalescent  
812 individuals. *MedRxiv*, 2021.12.08.21267491.  
813 <https://doi.org/10.1101/2021.12.08.21267491>
- 814 Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021). Immunological mechanisms of  
815 vaccine-induced protection against COVID-19 in humans. *Nature Reviews Immunology*  
816 *2021 21:8*, 21(8), 475–484. <https://doi.org/10.1038/s41577-021-00578-z>
- 817 Selva, K. J., van de Sandt, C. E., Lemke, M. M., Lee, C. Y., Shoffner, S. K., Chua, B. Y., Davis, S.  
818 K., Nguyen, T. H. O., Rowntree, L. C., Hensen, L., Koutsakos, M., Wong, C. Y., Mordant,  
819 F., Jackson, D. C., Flanagan, K. L., Crowe, J., Tosif, S., Neeland, M. R., Sutton, P., ...  
820 Chung, A. W. (2021a). Systems serology detects functionally distinct coronavirus  
821 antibody features in children and elderly. *Nature Communications 2021 12:1*, 12(1), 1–  
822 14. <https://doi.org/10.1038/s41467-021-22236-7>
- 823 Stavnezer, J. (1996). Immunoglobulin class switching. *Current Opinion in Immunology*, 8(2),  
824 199–205. [https://doi.org/10.1016/S0952-7915\(96\)80058-6](https://doi.org/10.1016/S0952-7915(96)80058-6)
- 825 Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J.,  
826 Devilliers, H., Ghillani, P., Gunn, C., Hockett, R., Mudumba, S., Guihot, A., Luyt, C.-E.,  
827 Mayaux, J., Beurton, A., Fourati, S., Bruel, T., ... Gorochov, G. (2021). IgA dominates the  
828 early neutralizing antibody response to SARS-CoV-2. In *Sci. Transl. Med* (Vol. 13).  
829 <http://stm.sciencemag.org/>
- 830 Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussièrès, G., Brassard,  
831 N., Laumaea, A., Vézina, D., Prévost, J., Anand, S. P., Bourassa, C., Gendron-Lepage, G.,



- 832 Medjahed, H., Goyette, G., Niessl, J., Tastet, O., Gokool, L., Morrisseau, C., ... Finzi, A.  
833 (2021). A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody  
834 effector functions and T cell responses. *Cell Host and Microbe*.  
835 <https://doi.org/10.1016/j.chom.2021.06.001>
- 836 Tomaras, G. D., Ferrari, G., Shen, X., Alam, S. M., Liao, H. X., Pollara, J., Bonsignori, M.,  
837 Moody, M. A., Fong, Y., Chen, X., Poling, B., Nicholson, C. O., Zhang, R., Lu, X., Parks, R.,  
838 Kaewkungwal, J., Nitayaphan, S., Pitisuttithum, P., Rerks-Ngarm, S., ... Haynes, B. F.  
839 (2013). Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope  
840 blocks binding and effector function of IgG. *Proceedings of the National Academy of  
841 Sciences of the United States of America*, 110(22), 9019–9024.  
842 <https://doi.org/10.1073/PNAS.1301456110/-/DCSUPPLEMENTAL>
- 843 Tudor, D., Yu, H., Maupetit, J., Drillet, A. S., Bouceba, T., Schwartz-Cornil, I., Lopalco, L.,  
844 Tuffery, P., & Bomsel, M. (2012). Isotype modulates epitope specificity, affinity, and  
845 antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. *Proceedings  
846 of the National Academy of Sciences of the United States of America*, 109(31), 12680–  
847 12685. <https://doi.org/10.1073/PNAS.1200024109/-/DCSUPPLEMENTAL>
- 848 Ullah, I., Prévost, J., Ladinsky, M. S., Stone, H., Lu, M., Anand, S. P., Beaudoin-Bussi eres, G.,  
849 Symmes, K., Benlarbi, M., Ding, S., Gasser, R., Fink, C., Chen, Y., Tauzin, A., Goyette, G.,  
850 Bourassa, C., Medjahed, H., Mack, M., Chung, K., ... Uchil, P. D. (2021). Live imaging of  
851 SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function  
852 for optimal efficacy. *Immunity*, 54(9), 2143.  
853 <https://doi.org/10.1016/J.IMMUNI.2021.08.015>
- 854 Verkerke, H., Saeedi, B. J., Boyer, D., Allen, J. W., Owens, J., Shin, S., Horwath, M., Patel, K.,  
855 Paul, A., Wu, S., Wang, J., Ho, A., Maier, C. L., Zerra, P. E., Chonat, S., Arthur, C. M.,  
856 Roback, J. D., Neish, A. S., Lough, C., ... Stowell, S. R. (2021). Are We Forgetting About  
857 IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma. *Transfusion*,  
858 61(6), 1740. <https://doi.org/10.1111/TRF.16435>
- 859 Verma, J., & Subbarao, N. (2021). Insilico study on the effect of SARS-CoV-2 RBD hotspot  
860 mutants' interaction with ACE2 to understand the binding affinity and stability.  
861 *Virology*, 561, 107–116. <https://doi.org/10.1016/J.VIROL.2021.06.009>
- 862 Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M.,  
863 Hoffmann, H. H., Oliveira, T. Y., Oren, D. A., Ramos, V., Nogueira, L., Michailidis, E.,  
864 Robbiani, D. F., Gazumyan, A., Rice, C. M., Hatzioannou, T., Bieniasz, P. D., Caskey, M.,  
865 & Nussenzweig, M. C. (2021). Enhanced SARS-CoV-2 neutralization by dimeric IgA.  
866 *Science Translational Medicine*, 13(577), 1555.  
867 <https://doi.org/10.1126/scitranslmed.abf1555>
- 868 Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R.  
869 K., Eugenia Dieterle, M., Lilov, A., Huang, D., Tse, L. v., Johnson, N. v., Hsieh, C. L.,  
870 Wang, N., Nett, J. H., Champney, E., Burnina, I., Brown, M., Lin, S., ... Walker, L. M.  
871 (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies.  
872 *Science*, 369(6504), 731–736.  
873 [https://doi.org/10.1126/SCIENCE.ABC7424/SUPPL\\_FILE/PAP.PDF](https://doi.org/10.1126/SCIENCE.ABC7424/SUPPL_FILE/PAP.PDF)
- 874 Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H. X., Lee, W. S., Wragg,  
875 K. M., Kelly, H. G., Esterbauer, R., Davis, S. K., Kent, H. E., Mordant, F. L., Schlub, T. E.,  
876 Gordon, D. L., Khoury, D. S., Subbarao, K., Cromer, D., Gordon, T. P., ... Kent, S. J.  
877 (2021). Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.  
878 *Nature Communications*, 12(1). <https://doi.org/10.1038/s41467-021-21444-5>

- 879 Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H.,  
880 Huang, Y., Allen, J. D., Case, J. B., Sutton, R. E., Carnahan, R. H., Darling, T. L., Boon, A. C.  
881 M., Mack, M., Head, R. D., Ross, T. M., Crowe, J. E., & Diamond, M. S. (2021). Human  
882 neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for  
883 optimal therapeutic protection. *Cell*, *184*(7), 1804-1820.e16.  
884 <https://doi.org/10.1016/j.cell.2021.02.026>
- 885 Wrapp, D., Wang, N., Corbett, K., & ... J. G. (2020). Cryo-EM structure of the 2019-nCoV  
886 spike in the prefusion conformation. *Science.Sciencemag.Org*.  
887 <https://science.sciencemag.org/content/367/6483/1260.abstract>
- 888 Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman,  
889 J., Hauser, B. M., Caradonna, T., Schmidt, A. G., Cai, Y., Streeck, H., Ryan, E. T., Barouch,  
890 D. H., Charles, R. C., Lauffenburger, D. A., & Alter, G. (2020). Compromised Humoral  
891 Functional Evolution Tracks with SARS-CoV-2 Mortality. *Cell*, *183*(6), 1508-1519.e12.  
892 <https://doi.org/10.1016/J.CELL.2020.10.052>  
893




Fig. 1.






Fig. 2.




Fig. 3.




Fig. 4.